No products in the cart.
Pre-Made Alvircept Sudotox biosimilar, Fusion Protein: Recombinant therapeutic protein targeting HIV-1 gp120 fused with Pseudomonas aeruginosa exotoxin A for drug discovery and mechanism of action (MOA) research
Cat:GMP-Bios-INN-731
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Alvircept Sudotox biosimilar, Fusion Protein: Recombinant therapeutic protein targeting HIV-1 gp120 fused with Pseudomonas aeruginosa exotoxin A is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Alvircept sudotox is a form of recombinant CD4 derived from Pneumonas aeruginosa exotoxin A, or ‘PE4, which has a size of 59,187 daltons and is an anti-viral agent.[1]
Alvircept sudotox is a form of recombinant CD4 derived from Psedomonas aeruginosa exotoxin A, or ‘PE40¡¯ as an anti-viral agent. Alvircept Sudotox has been used in trials studying the treatment of HIV Infections.
| Products Name (INN Index) | Pre-Made Alvircept Sudotox biosimilar, Fusion Protein: Recombinant therapeutic protein targeting HIV-1 gp120 fused with Pseudomonas aeruginosa exotoxin A |
|---|---|
| INN Name | alvircept sudotox |
| Target | HIV-1 gp120 |
| Format | Fusion Protein |
| Derivation | Pseudomonas aeruginosa Human |
| Species Reactivity | Human |
| CH1 Isotype | Fusion – CD4 (p55, T cell surface antigen T4/Leu-3) – Pseudomonas aeruginosa exotoxin A |
| VD LC | Fusion – CD4 (p55, T cell surface antigen T4/Leu-3) – Pseudomonas aeruginosa exotoxin A |
| Highest_Clin_Trial (Jan '20) | NA |
| Est. Status | NA |
| 100% SI Structure | NA |
| 99% SI Structure | NA |
| 95-98% SI Structure | NA |
| Year Proposed | NA |
| Year Recommended | NA |
| Companies | National?Institute?of Allergy???and Infectious?Diseases (NIAID) (Bethesda USA) |
| Conditions Approved | NA |
| Conditions Active | NA |
| Conditions Discontinued | NA |
| Development Tech | NA |
| Previous Name | NA |
| Gm Offical Target Name | HIV-1 gp120 |
| Package |
Previous slide
Next slide
